Antibe Therapeutics (ATBPF)
OTHER OTC:ATBPF
US Market
Holding ATBPF?
Track your performance easily

Antibe Therapeutics (ATBPF) Technical Analysis

107 Followers

Summary of all the Indicators

Overall Consensus
Sell
5Bullish
5Neutral
10Bearish
Technical Analysis Consensus
Sell
1Bullish
5Neutral
2Bearish
Moving Average Consensus
Sell
4Bullish
0Neutral
8Bearish
Antibe Therapeutics’s (ATBPF) Moving Averages Convergence Divergence (MACD) indicator is >-0.01, suggesting Antibe Therapeutics is a Sell.
Antibe Therapeutics’s (ATBPF) 20-Day exponential moving average is 0.22, while Antibe Therapeutics’s (ATBPF) share price is $0.216, making it a Sell.
Antibe Therapeutics’s (ATBPF) 50-Day exponential moving average is 0.22, while Antibe Therapeutics’s (ATBPF) share price is $0.216, making it a Sell.

Antibe Therapeutics (ATBPF) Pivot Points

Nov 12, 2024, 10:02 PM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
0.13
0.16
0.19
0.22
0.25
0.27
0.30
Fibonacci
0.16
0.18
0.20
0.22
0.24
0.25
0.27
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Antibe Therapeutics (ATBPF) Moving Averages

Nov 12, 2024, 10:02 PM
Period
Simple
Exponential
MA5
0.22Buy
0.22Buy
MA10
0.22Sell
0.22Sell
MA20
0.22Sell
0.22Sell
MA50
0.22Buy
0.22Sell
MA100
0.22Buy
0.24Sell
MA200
0.29Sell
0.33Sell
Antibe Therapeutics’s (ATBPF) 10-Day exponential moving average is 0.22, while Antibe Therapeutics’s (ATBPF) share price is $0.216, making it a Sell.
Antibe Therapeutics’s (ATBPF) 100-Day exponential moving average is 0.24, while Antibe Therapeutics’s (ATBPF) share price is $0.216, making it a Sell.
Antibe Therapeutics’s (ATBPF) stock price is $0.216 and Antibe Therapeutics’s (ATBPF) 50-day simple moving average is 0.22, creating a Buy signal.
Antibe Therapeutics’s (ATBPF) stock price is $0.216 and Antibe Therapeutics’s (ATBPF) 100-day simple moving average is 0.22, creating a Buy signal.
Antibe Therapeutics’s (ATBPF) stock price is $0.216 and Antibe Therapeutics’s (ATBPF) 200-day simple moving average is 0.29, creating a Sell signal.

Antibe Therapeutics (ATBPF) Technical Indicators

Nov 12, 2024, 10:02 PM
Name
Value
Implied Action
RSI (14)
35.70
Neutral
STOCH (9,6)
56.14
Neutral
STOCHRSI (14)
56.14
Neutral
MACD (12,26)
>-0.01
Sell
ADX (14)
39.21
Neutral
Williams %R
-43.86
Buy
CCI (14)
0.00
-
ATR (14)
0.06
-
Ultimate Oscillator
56.14
Neutral
ROC
0.00
-
Antibe Therapeutics’s (ATBPF) Relative Strength Index (RSI) is 35.70, creating a Neutral signal.
Antibe Therapeutics’s (ATBPF) Trend Strength Indicator (ADX) is 39.21, creating a Neutral signal.

FAQ

Is ATBPF a Buy, Hold, or Sell?
Based on ATBPF’s technical indicators, ATBPF is a Sell.
    What is ATBPF’s RSI (14)?
    ATBPF’s RSI (14) is 35.70, which suggests ATBPF is a Neutral.
      What is ATBPF’s MACD?
      ATBPF’s MACD is >-0.01, which suggests ATBPF is a Sell.
        What is ATBPF’s 5-day moving average?
        ATBPF’s 5-day moving average is 0.22, which suggests ATBPF is a Buy.
          What is ATBPF’s 20-day moving average?
          ATBPF 20-day moving average is 0.22, which suggests ATBPF is a Sell.
            What is ATBPF’s 50-day moving average?
            ATBPF’s 50-day moving average is 0.22, which suggests ATBPF is a Buy.
              What is ATBPF’s 200-day moving average?
              ATBPF’s 200-day moving average is 0.29, which suggests ATBPF is a Sell.
                What is ATBPF’s Williams % R (14)?
                ATBPF’s Williams % R (14) is -43.86, which suggests ATBPF is a Buy.
                  What is ATBPF’s CCI (14)?
                  Currently, no data Available
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis